Investors and analysts rating Aurinia Pharmaceuticals a Buy are doing so based on its late-stage positioning in LN treatment. The FDA’s NDA fast-track approval shortens the research window to under 12 months, which means we’ll know by the end of 2021 whether the treatment works.
Similarly, Where is Aurinia pharmaceuticals?
Company Overview
Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company’s head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland.
Why is Aurinia stock dropping? Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022.
Thereof, What is the target price for BCRX stock?
Stock Price Targets
| High | $30.00 |
|---|---|
| Median | $17.50 |
| Low | $14.00 |
| Average | $19.50 |
| Current Price | $12.59 |
How many employees does Aurinia?
Compare AUPH With Other Stocks
| Aurinia Pharmaceuticals Inc Annual Number of Employees | |
|---|---|
| 2020 | 294 |
| 2019 | 62 |
| 2018 | 39 |
| 2017 | 33 |
Is Bcrx a buy right now?
BioCryst Pharmaceuticals has received a consensus rating of Buy.
Who owns BioCryst Pharmaceuticals?
State Street Global Advisors, Inc. is currently the largest shareholder, with 10% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.0% of common stock, and Baker Bros. Advisors LP holds about 7.2% of the company stock.
Why is BioCryst going up?
The big gain came after the company provided an upbeat update on Monday. BioCryst announced preliminary net revenue for hereditary angioedema (HAE) drug Orladeyo of $45.6 million for the fourth quarter of 2021. This figure brings the full-year 2021 sales for the drug to $122 million.
Is BioCryst Pharmaceuticals a good stock to buy?
Zacks’ proprietary data indicates that BioCryst Pharmaceuticals, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the BCRX shares relative to the market in the next few months.
Is BioCryst a good stock to buy?
Is BioCryst Pharmaceuticals stock A Buy? The BioCryst Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe BioCryst Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
What is BioCryst Pharmaceuticals working on?
BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg …
Where is BioCryst located?
BioCryst’s US headquarters is located in Durham, North Carolina, our European headquarters in Dublin, Ireland and our Discovery Center of Excellence in Birmingham, Alabama.
When did BioCryst go public?
When was BioCryst founded and when did the company go public? BioCryst was founded in 1986 and completed its Initial Public Offering in March 1994. The Company’s stock is traded on the NASDAQ exchange under the symbol BCRX.
Why did BioCryst stock drop?
Shares of BioCryst ( BCRX 1.65% ), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. A drop in top-line revenue and softer-than-expected guidance aren’t sitting well with investors, who have driven the stock 16.5% lower as of 11:50 a.m. on Wednesday.
What does BioCryst Pharmaceuticals do?
BioCryst is a commercial-stage biotech company that is committed to delivering extraordinary medicines that help patients live ordinary lives. We are passionate about advancing novel therapeutics for patients with rare and serious diseases.
How many employees does BioCryst have?
BioCryst Pharmaceuticals
| Type | Public |
|---|---|
| Key people | Jon P. Stonehouse , President and Chief Executive Officer |
| Products | RABIVAP |
| Revenue | $49 Million(2019) |
| Number of employees | 110 |
How many employees does biocryst have?
BioCryst Pharmaceuticals
| Type | Public |
|---|---|
| Key people | Jon P. Stonehouse , President and Chief Executive Officer |
| Products | RABIVAP |
| Revenue | $49 Million(2019) |
| Number of employees | 110 |
Join TheMoney.co community and don’t forget to share this post !
